Durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: Three-month follo
NBER WORKING PAPER SERIES WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS Dan Zeltzer Liran Einav Amy Finkels
Patients with cancer achieve response to messenger RNA COVID-19 vaccine
NBER on Twitter: "Sources of high end-of-life spending for cancer patients, from @danzeltzer, Liran Einav, Amy Finkelstein, Tzvi Shir, Salomon M. Stemmer, and Ran D. Balicer https://t.co/vyosdFbT3M https://t.co/VsajwVZKrx" / Twitter
Pasireotide for malignant insulinoma
A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells - Sofer - 2022 - The FASEB Journal - Wiley Online Library
A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic sol
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
White Matter Changes in Patients with Breast Cancer Treated with High-Dose Chemotherapy and Autologous Bone Marrow Support
Phase II organâ•'preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to
WP2: Resilience Definition and operationalization
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - Annals of Oncology
Cancers | Free Full-Text | Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy
Biomedicines | Free Full-Text | Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
This gives hope': A third COVID-19 vaccine dose can boost protection for organ transplant recipients | Science | AAAS
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
Trajectories of Injectable Cancer Drug Costs After Launch in the United States | Journal of Clinical Oncology
Prof. Salomon Stemmer – CTG-Pharma
ESMO Congress 2021 Speakers Template
Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
